269 related articles for article (PubMed ID: 29228819)
1. Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3
Barse RK; Tagalpallewar AA; Kokare CR; Sharma JP; Sharma PK
Drug Dev Ind Pharm; 2018 May; 44(5):800-807. PubMed ID: 29228819
[TBL] [Abstract][Full Text] [Related]
2. Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for Ocular Delivery of Dorzolamide HCl: In Vitro, In Vivo, and Ex Vivo Evaluation.
Kouchak M; Mahmoodzadeh M; Farrahi F
AAPS PharmSciTech; 2019 Jun; 20(5):210. PubMed ID: 31161269
[TBL] [Abstract][Full Text] [Related]
3. Increasing efficacy and reducing systemic absorption of brimonidine tartrate ophthalmic gels in rabbits.
Pang X; Li J; Pi J; Qi D; Guo P; Li N; Wu Y; Liu Z
Pharm Dev Technol; 2018 Mar; 23(3):231-239. PubMed ID: 28488447
[TBL] [Abstract][Full Text] [Related]
4. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study.
Singh J; Chhabra G; Pathak K
Drug Dev Ind Pharm; 2014 Sep; 40(9):1223-32. PubMed ID: 23837522
[TBL] [Abstract][Full Text] [Related]
5. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.
Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M
Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613
[TBL] [Abstract][Full Text] [Related]
6. Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system.
Geethalakshmi A; Karki R; Jha SK; Venkatesh DP; Nikunj B
Curr Drug Deliv; 2012 Mar; 9(2):197-204. PubMed ID: 22283647
[TBL] [Abstract][Full Text] [Related]
7. Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma.
Sharma PK; Chauhan MK
Curr Eye Res; 2021 Nov; 46(11):1703-1716. PubMed ID: 33844617
[No Abstract] [Full Text] [Related]
8. Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits.
Fouda NH; Abdelrehim RT; Hegazy DA; Habib BA
Drug Deliv; 2018 Nov; 25(1):1340-1349. PubMed ID: 29869516
[TBL] [Abstract][Full Text] [Related]
9. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.
Patel N; Nakrani H; Raval M; Sheth N
Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408
[TBL] [Abstract][Full Text] [Related]
10. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide.
Morsi N; Ibrahim M; Refai H; El Sorogy H
Eur J Pharm Sci; 2017 Jun; 104():302-314. PubMed ID: 28433750
[TBL] [Abstract][Full Text] [Related]
11. Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy: Preparation, Characterization and Pharmacodynamic Study.
Gautam N; Kesavan K
Curr Eye Res; 2021 Dec; 46(12):1844-1852. PubMed ID: 34176380
[No Abstract] [Full Text] [Related]
12. Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin.
Wu C; Qi H; Chen W; Huang C; Su C; Li W; Hou S
Yakugaku Zasshi; 2007 Jan; 127(1):183-91. PubMed ID: 17202799
[TBL] [Abstract][Full Text] [Related]
13. Cationic liposomes as promising vehicles for timolol/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro/in vivo evaluation.
Bigdeli A; Makhmalzadeh BS; Feghhi M; SoleimaniBiatiani E
Drug Deliv Transl Res; 2023 Apr; 13(4):1035-1047. PubMed ID: 36477776
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation.
Aburahma MH; Mahmoud AA
AAPS PharmSciTech; 2011 Dec; 12(4):1335-47. PubMed ID: 21979886
[TBL] [Abstract][Full Text] [Related]
15. Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.
Kim SN; Ko SA; Park CG; Lee SH; Huh BK; Park YH; Kim YK; Ha A; Park KH; Choy YB
Mol Pharm; 2018 Aug; 15(8):3143-3152. PubMed ID: 30020792
[TBL] [Abstract][Full Text] [Related]
16. New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system.
Cao F; Zhang X; Ping Q
Drug Deliv; 2010; 17(7):500-7. PubMed ID: 20500130
[TBL] [Abstract][Full Text] [Related]
17. Cubic and hexagonal liquid crystal gels for ocular delivery with enhanced effect of pilocarpine nitrate on anti-glaucoma treatment.
Xingqi W; Yong Z; Xing L; Yang W; Jie H; Rongfeng H; Shuangying G; Xiaoqin C
Drug Deliv; 2019 Dec; 26(1):952-964. PubMed ID: 31544551
[TBL] [Abstract][Full Text] [Related]
18. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.
Bhagav P; Upadhyay H; Chandran S
AAPS PharmSciTech; 2011 Dec; 12(4):1087-101. PubMed ID: 21879393
[TBL] [Abstract][Full Text] [Related]
19. Optimization of a novel in situ gel for sustained ocular drug delivery using Box-Behnken design: In vitro, ex vivo, in vivo and human studies.
Ranch KM; Maulvi FA; Naik MJ; Koli AR; Parikh RK; Shah DO
Int J Pharm; 2019 Jan; 554():264-275. PubMed ID: 30423418
[TBL] [Abstract][Full Text] [Related]
20. Novel topical ophthalmic formulations for management of glaucoma.
Ibrahim MM; Abd-Elgawad AE; Soliman OA; Jablonski MM
Pharm Res; 2013 Nov; 30(11):2818-31. PubMed ID: 23771565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
